Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| As we've refined our sales and marketing expenses, UPNEEQ continues to deliver tremendous success in the early stages of this market build |
| UPNEEQ continues to perform in the market, delivering consistent satisfaction for both providers and patients |
| But we feel really good about the impact the product has |
| The Company made some nice strides in terms of trimming expenses year-over-year |
| Clearly, our strategy with the sales force has established a strong baseline of provider acceptance and real-world data, which reinforces the value proposition of the product |
| In closing, we have established a strong foundation for future growth, coupling a tremendous product with enhanced technology, while further optimizing our marketing mix to better align with the drivers of growth for the next phase of our evolution |
| First, UPNEEQ, our one and only prescription product for Blepharoptosis or Droopy eyelid, continues to build momentum across our three channels |
| These fundamentals combined with our streamlined sales organization leave us well positioned to extract significant value from an investment in consumer awareness |
| Not only does this foundation help to position UPNEEQ for future growth but as we focus on business development, our platform provides a tremendous opportunity to forward integrate and or add products |
| Though we remain in the early days, the Elevate launch is off to a great start, and we expect this capability to deliver increasing value to the business, providers and our patients as we continue the rollout |
| So whatever we do to activate the consumer, we should see the benefit of that and a much greater return on investment than what's typical in the industry and our brand has elite patient satisfaction |
| With UPNEEQ, we have also launched a novel therapy poised for accelerating growth |
| Patient satisfaction remains strong across our growing user base and we have even had a growing number of investigator studies completed and or published, which highlights the quality of life impact UPNEEQ has in mild Ptosis |
| This progress in learning has allowed us to create an incredibly strong foundation for future growth |
| And so this platform, one of the things that it does is gives us the ability to drive that behavior and so far, so good |
| So for us, where we have some of the greatest success in terms of beginning to turn the wheel is an opportunity when our people are in there supporting events, patient-focused events within the practice and the patients are directly hearing the story in a clear and consistent manner, which prompts intrigue intent to trial and subsequent conversion |
| Moreover, we continue to see steady increases in the number of reordering aesthetic accounts which as of the end of the second quarter exceeded 2100, an increase of over 300 since Q1 |
| So we're excited about it |
| Building upon the introduction, we are excited by the momentum being created by the Company and UPNEEQ |
| In short, we have created strong validation of product efficacy in the real world, coupled with two and a half years of a safety database |
| And we're very excited about what we think those seeds will bloom into |
| However, I am pleased to report the conversions to the new system are ahead of our internal expectations |
| But look, I think they're both important, right, the B2B2C side, the technological enhancements that we've developed and launched as of early July, create a very unique connection at the practice, where patients that now initiate therapy in over 6,500 of our locations where providers are dispensing directly UPNEEQ now have seamless ongoing access to the product via this technology and our pharmacy |
| Moreover, the rollout to providers has exceeded our expectations as over 2,000 accounts have already been migrated about 30% of the total with about 1,200 having a confirmed strike connected account already |
| That is clearly still the single biggest value driver and something we remain keen on accelerating and extracting maximum value as we move forward |
| As you can see on the slide, we have established a broad and continuously expanding foundation of provider acceptance and subsequent access points for patients |
| So look, we're excited about what this serves for both UPNEEQ and potentially future products as we go |
| The product is as advertised, delivering time and again, both efficacy and safety across a growing base of what we believe is more than 250,000 paid patients |
| For patients Elevate offers the ability to enter a subscription-based auto refill program, making access to UPNEEQ seamless and more affordable |
| Specific to the second quarter, our provider base has expanded to more than 21,000 prescribers and over 6,600 aesthetic and eye care practices with direct dispense capability, an increase of over 1,000 and about 400, respectively, since Q1 |
| Statement |
|---|
| Third, during the quarter, we continued to reduce operating expenses which has had a modest negative effect on our top line revenue of $8.3 million in the quarter |
| Lastly, our adjusted EBITDA loss for Q2 was $7.4 million nearly 40% lower than the comparable EBITDA loss of $11.8 million in the prior year quarter |
| Net product sales relating entirely to UPNEEQ were $8.3 million in the second quarter of 2023, reflecting a slight decrease from prior year |
| The change was due to a year-over-year decrease in sales volume, partly offset by nominally higher pricing from a price increase put in during April of last year |
| Unique to the second quarter of 2023 and following our recent discontinuance of marketing efforts associated with arbaclofen we recognized impairment charges of $13.9 million to write off the asset |
| Unaided, this awareness drops to zero |
| The decrease was primarily driven by lower sales volumes and royalty expense inclusive of contingent earn-out obligations unique to the 2022 period |
| Total cost of goods sold for Q2 decreased by $0.3 million to $1.9 million in the three months ended June 30, 2023 |
| R&D expenses for Q2 decreased by $0.7 million or by just over half year-over-year to only $0.5 million due to lower compensation lower project spending and lower share-based compensation expense |
| I don't think there's been negative reaction to the product, but I think doing anything new, if you think about the average practice is a heavy lift |
| SG&A expenses decreased by $6.3 million or by nearly one third year-over-year to only $13.9 million in the 2023 period |
| After adjusting for nonrecurring or exceptional items and noncash share-based comp, our second quarter monthly TOE spend was solidly below $5 million well short of the $7 million benchmark we had set |
| Also, we're fighting for attention amongst a plethora of other products, devices, services that are being offered to the aesthetic practitioner and anything we can do to build the portfolio to make us more relevant can only be helpful |
| And I think one of the things that we found is without some more levers to toggle we're not optimizing the opportunity to build this market at an accelerating pace |
| Brian Markison Well, Michaela, I think we're so underpenetrated in general with the aesthetic practices in the world, I think -- I don't think we're really subject to a lot of economic headwinds at the moment |
| So I think we have an answer for headwinds |
| Involve risks and uncertainties, including those noted in today's press release and the Company's filings with the Securities and Exchange Commission |
| And that's something we just have not done to date |
Please consider a small donation if you think this website provides you with relevant information